The logo of the biotech company Curevac in Tübingen
The Tübingen-based company Curevac announced that its corona vaccine candidate had a preliminary effectiveness of only 47 percent. Furthermore, the effectiveness would depend on the age of the test subjects and the virus strain present.
I.In an effort to launch a highly effective corona vaccine, the Tübingen-based pharmaceutical company Curevac has suffered a setback. According to an interim analysis, the Curevac vaccine candidate CVnCoV only achieved a preliminary effectiveness of 47 percent against corona disease “of any severity” and thus did not meet the specified statistical success criteria, announced the Tübingen-based company in a mandatory announcement on Wednesday evening.
“In a previously unprecedented environment with at least 13 variants within the subset of study participants examined in this interim analysis, CVnCoV achieved a preliminary effectiveness of 47 percent against COVID-19 disease of any severity and thus did not meet the specified statistical success criteria.” traded Curevac shares collapsed in after-hours trading by almost 40 percent.
Initial analyzes have shown that the effectiveness depends on the age group examined and the strain of the virus, it said. The Data Safety Monitoring Board (DSMB) has confirmed a good safety profile and the study will continue until the final analysis.
The first-generation vaccine candidate is in the final stages of clinical development. An initial interim analysis did not reveal any safety concerns. Curevac works with Bayer.